Stay updated on Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial
Sign up to get notified when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.

Latest updates to the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page
- CheckyesterdayChange DetectedPage revision updated from v3.6.0 to v3.6.2, indicating a newer build of the study page.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedEnrollment status is updated to 'No longer looking for participants', clarifying that recruitment has ended. The page also adds or reorganizes helpful sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment header to reflect current content structure.SummaryDifference0.4%

- Check22 days agoChange DetectedThe study plan section was updated to replace and augment several safety and efficacy endpoints with standardized definitions (e.g., DLT rate by CTCAE v5.0, ORR by RECIST v1.1, and PFS/OS) and to include a comprehensive set of pharmacokinetic endpoints. Older endpoint definitions (per-dose-level DLT rate, peak PK measures, and certain PK analyses) were removed and clarified to align with current terminology.SummaryDifference1%

- Check43 days agoChange DetectedA new revision tag 'Revision: v3.5.4' was added and the previous 'Revision: v3.5.3' was removed, indicating a deployment/build update reflected on the page.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page footer revision identifier has been updated from v3.5.2 to v3.5.3, indicating a site/display software revision rather than a change to the clinical trial record content.SummaryDifference0.0%

- Check72 days agoChange DetectedRevision history updated: added v3.5.2 and removed v3.5.0.SummaryDifference0.0%

Stay in the know with updates to Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.